作者
Jean-Pascal Lefaucheur, Nathalie André-Obadia, Andrea Antal, Samar S Ayache, Chris Baeken, David H Benninger, Roberto M Cantello, Massimo Cincotta, Mamede de Carvalho, Dirk De Ridder, Hervé Devanne, Vincenzo Di Lazzaro, Saša R Filipović, Friedhelm C Hummel, Satu K Jääskeläinen, Vasilios K Kimiskidis, Giacomo Koch, Berthold Langguth, Thomas Nyffeler, Antonio Oliviero, Frank Padberg, Emmanuel Poulet, Simone Rossi, Paolo Maria Rossini, John C Rothwell, Carlos Schönfeldt-Lecuona, Hartwig R Siebner, Christina W Slotema, Charlotte J Stagg, Josep Valls-Sole, Ulf Ziemann, Walter Paulus, Luis Garcia-Larrea
发表日期
2014/11/1
来源
Clinical Neurophysiology
卷号
125
期号
11
页码范围
2150-2206
出版商
Elsevier
简介
A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for …
学术搜索中的文章
JP Lefaucheur, N André-Obadia, A Antal, SS Ayache… - Clinical Neurophysiology, 2014